JAZZ · Jazz Pharmaceuticals plc
United States · RS rating 65 · As of 2026-11-03
| Price | 229.74 USD |
|---|---|
| 1-day change | +7.1% |
| RS rating (overall / 1M / 3M / 12M) | 65 / 50 / 42 / 89 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 35 / 29 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | -21.3% |
| Sales growth Q/Q | +6.4% |
| Distance from 52-week high | +12.2% |
| Market cap (USD) | $12.3B |